Picture [iito] Made Without Love 650x80px
Document › Details

Araris Biotech AG. (8/20/19). "Press Release: Araris Biotech AG Closes Seed Financing Round of CHF 2.5 Million". Zurich.

Organisations Organisation Araris Biotech AG
  Organisation 2 Redalpine Venture Partners AG
Products Product antibody-drug conjugates (ADC) technology
  Product 2 venture capital
Index term Index term Araris Biotech–SEVERAL: investment, 201908 seed financing round CHF2.5m with Redalpine + Schroder Adveq + VI Partners
Persons Person Spycher, Philipp (Araris Biotech 201902– CEO + Co-Founder)
  Person 2 Grabulovski, Dragan (Covagen 200701– CSO + co-founder)

> Redalpine, Schroder Adveq and VI Partners participated in round

> Proceeds to support development of own antibody-drug-conjugates (ADCs)

Araris Biotech AG announced today the closing of an oversubscribed seed financing round of CHF 2.5 million with participation of Swiss investors Redalpine, Schroder Adveq and VI Partners. The proceeds will be used to develop a pipeline of proprietary antibody-drug conjugates (ADCs).

Araris’ co-founder and Chief Executive Officer, Dr. Philipp Spycher, commented: “We are very pleased to announce that three renowned Swiss investors with a very strong track record have invested in Araris.”

Dr. Dragan Grabulovski, co-founder and chairman of the board, added: “Obtaining a seed financing from VCs just six months after incorporation of Araris validates the strong interest in our novel linker ADC technology. The funding will allow Araris to progress quickly towards generating key proof of principle data.”

For further details, please contact:
Araris Biotech AG
Dr. Philipp Spycher, CEO

About Araris Biotech AG:

Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich focusing on the commercialization of a novel antibody-drug conjugate (ADC)-linker technology. Araris' innovative platform allows for the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering. The resulting ADCs have a well-defined drug-to-antibody ratio, are stable and monomeric. All these favorable properties contribute to the high efficacy and low level of toxicity observed so far. In summary, the straightforward drug conjugation, versatility of the technology and high in vivo efficacy enable the generation of ADC compounds for the treatment of patients with a high unmet medical need.

For more information, please visit

Record changed: 2019-08-22


Picture [iito] Plain Stupid Simple 650x80px

More documents for Araris Biotech AG

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture EBD Group Global Partnering Four Events One Price 650x80

» top